PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus

Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51.e1–8.

Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet. 2000;356(9243):1735–6.

U.S. Food and Drug Administration Pregnant women: scientific and ethical considerations for inclusion in clinical trials guidance for industry [Internet]. 2018. Available from: https://www.fda.gov/media/112195/download

European Medicines Agency. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling [Internet]. 2009. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling_en.pdf

Brent RL. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics. 2004 Apr;113(4 Suppl):984–95.

European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data [Internet]. 2006. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf

Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res Part C Embryo Today Rev. 2015;105(2):140–56.

Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365–96.

Abduljalil K, Johnson TN, Rostami-Hodjegan A. Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin Pharmacokinet. 2018;57(9):1149–71.

Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56(11):1303–30.

Marsousi N, Desmeules JA, Rudaz S, Daali Y. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci. 2017;106(9):2380–91.

Luecke RH, Wosilait WD, Pearce BA, Young JF. A computer model and program for xenobiotic disposition during pregnancy. Comput Methods Prog Biomed. 1997;53(3):201–24.

De Sousa MM, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015;80(5):1031–41.

Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos. 2013;41(4):801–13.

Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. Clin Pharmacokinet. 2017;56(12):1525–41.

Xia B, Heimbach T, Gollen R, Nanavati C, He H. A Simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013;15(4):1012–24.

De Sousa MM, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, et al. A physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet. 2017;56(5):537–50.

Zhang Z, Imperial MZ, Patilea-Vrana GI, Wedagedera J, Gaohua L, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos Biol Fate Chem. 2017;45(8):920–38.

Zhang Z, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs. Drug Metab Dispos Biol Fate Chem. 2017;45(8):939–46.

Carmichael S, Abrams B, Selvin S. The pattern of maternal weight gain in women with good pregnancy outcomes. Am J Public Health. 1997;87(12):1984–8.

Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight gain during pregnancy: reexamining the guidelines [Internet]. Rasmussen KM, Yaktine AL, editors. Washington (DC): National Academies Press (US); 2009 [cited 2020 Jul 28]. (The National Academies Collection: Reports funded by National Institutes of Health). Available from: http://www.ncbi.nlm.nih.gov/books/NBK32813/

Jopling J, Henry E, Wiedmeier SE, Christensen RD. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics. 2009;123(2):e333–7.

Rubin MI, Bruck E, Rapoport M, Snively M, McKay H, Baumler A. Maturation of renal function in childhood: clearance studies. J Clin Invest. 1949;28(5 Pt 2):1144–62.

Yanowitz TD, Yao AC, Pettigrew KD, Werner JC, Oh W, Stonestreet BS. Postnatal hemodynamic changes in very-low-birthweight infants. J Appl Physiol Bethesda Md 1985. 1999;87(1):370–80.

Brace RA. Progress toward understanding the regulation of amniotic fluid volume: water and solute fluxes in and through the fetal membranes. Placenta. 1995;16(1):1–18.

Underwood M. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–8.

Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341–8.

Brace RA, Anderson DF, Cheung CY. Regulation of amniotic fluid volume: mathematical model based on intramembranous transport mechanisms. Am J Phys Regul Integr Comp Phys. 2014;307(10):R1260–73.

Lukacova V, Parrott NJ, Fraczkiewicz G, Bolger MB, Woltosz WS. General approach to calculation of tissue:plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling. AAPS Annual Meeting; 2008; Atlanta.

Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci. 2000;89(1):16–35.

Verhagen CA, Mattie H, Van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol. 1994;37(2):193–7.

Sakurai Y, Motohashi H, Ueo H, Masuda S, Saito H, Okuda M, et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004;21(1):61–7.

Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol. 2007;71(6):1591–7.

Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 1976;9(5):741–7.

Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol. 1982;142(7):823–8.

Holt DE, Fisk NM, Spencer JA, de Louvois J, Hurley R, Harvey D. Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume. Arch Dis Child. 1993;68(1):54–7.

Holt DE, Broadbent M, Spencer JA, de Louvois J, Hurley R, Harvey D. The placental transfer of cefuroxime at parturition. Eur J Obstet Gynecol Reprod Biol. 1994;54(3):177–80.

Oswald S, Müller J, Neugebauer U, Schröter R, Herrmann E, Pavenstädt H, et al. Protein abundance of clinically relevant drug transporters in the human kidneys. Int J Mol Sci. 2019;24(20):21.

Ueo H, Motohashi H, Katsura T, Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005;70(7):1104–13.

Uwai Y, Saito H, Inui K-I. Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet. 2002;17(2):125–9.

Smyth RD, Pfeffer M, Donald AG, Van Harken R, Hottendorf GH. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother. 1979;16(5):615–21.

Singhvi SM, Heald AF, Schreiber EC. Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations. Chemotherapy. 1978;24(3):121–33.

Rattie ES, Ravin LJ. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. Antimicrob Agents Chemother. 1975;7(5):606–13.

Lee FH, Pfeffer M, Van Harken DR, Smyth RD, Hottendorf GH. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother. 1980;17(2):188–92.

Shimizu T. Studies on protein binding of cefazolin and other antibiotics. Jpn J Antibiot. 1974;27(3):296–301.

Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12(2):136–44.

Elkomy MH, Sultan P, Drover DR, Epshtein E, Galinkin JL, Carvalho B. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. Antimicrob Agents Chemother. 2014;58(6):3504–13.

Fiore Mitchell T, Pearlman MD, Chapman RL, Bhatt-Mehta V, Faix RG. Maternal and transplacental pharmacokinetics of cefazolin. Obstet Gynecol. 2001;98(6):1075–9.

Brown CE, Christmas JT, Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol. 1990;163(3):938–43.

Zhang Z, Imperial MZ, Patilea-Vrana GI, Wedagedera J, Gaohua L, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos. 2017;45(8):920–38.

Zhang Z, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs. Drug Metab Dispos Biol Fate Chem. 2017;45(8):939–46.

Abduljalil K, Badhan RKS. Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2020;47(4):319–40.

De Sousa MM, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81(4):646–57.

Dallmann A, Pfister M, van den Anker J, Eissing T. Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clin Pharmacol Ther. 2018;104(6):1110–24.

Liu XI, Momper JD, Rakhmanina N, van den Anker JN, Green DJ, Burckart GJ, et al. Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol. 2020;60(2):240–55.

Chaphekar N, Caritis S, Venkataramanan R. Model-informed dose optimization in pregnancy. J Clin Pharmacol. 2020;60(S1):S63–76.

Song L, Yu Z, Xu Y, Li X, Liu X, Liu D, et al. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Biopharm Drug Dispos. 2020;41(6):248–67.

Codaccioni M, Bois F, Brochot C. Placental transfer of xenobiotics in pregnancy physiologically-based pharmacokinetic models: structure and data. Comput Toxicol. 2019;12:100111.

Codaccioni M, Brochot C. Assessing the impacts on fetal dosimetry of the modelling of the placental transfers of xenobiotics in a pregnancy physiologically based pharmacokinetic model. Toxicol Appl Pharmacol. 2020;409:115318.

Walker N, Filis P, Soffientini U, Bellingham M, O’Shaughnessy PJ, Fowler PA. Placental transporter localization and expression in the human: the importance of species, sex, and gestational age differences†. Biol Reprod. 2017;96(4):733–42.

Dallmann A, Liu XI, Burckart GJ, van den Anker J. Drug transporters expressed in the human placenta and models for studying maternal-fetal drug transfer. J Clin Pharmacol. 2019;59(S1):S70–81.

Anoshchenko O, Prasad B, Neradugomma NK, Wang J, Mao Q, Unadkat JD. Gestational age–dependent abundance of human placental transporters as determined by quantitative targeted proteomics. Drug Metab Dispos. 2020;48(9):735–41.